NCT02976779View on ClinicalTrials.gov

A Phase I, Double Blind, Randomized, Placebo Controlled, Maximal Dose Study to Determine the Safety, Tolerability of Topical Cream Containing MGC (Medical Grade Cannabis) in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 3, 2017

Primary Completion Date

January 25, 2019

Study Completion Date

January 25, 2019

Conditions

Safety Study for Future Treatment of Psoriasis

Interventions

DRUG

OWC MGC cream

Topical cream containing 3% CBD and 3% THC for Psoriasis treatment

DRUG

OWC Control Cream

Topical Cream without active ingredients

Trial Locations (1)

Unknown

Sheba Medical Center, Ramat Gan

All Listed Sponsors

lead

One World Cannabis Ltd.

INDUSTRY

NCT02976779 - A Phase I, Double Blind, Randomized, Placebo Controlled, Maximal Dose Study to Determine the Safety, Tolerability of Topical Cream Containing MGC (Medical Grade Cannabis) in Healthy Volunteers | Biotech Hunter | Biotech Hunter